{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:10:54Z","timestamp":1779905454957,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Menarini International Operations Luxembourg S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s12325-018-0697-x","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T07:19:52Z","timestamp":1523949592000},"page":"604-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study"],"prefix":"10.1007","volume":"35","author":[{"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Omboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"697_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160:1273\u201392.","journal-title":"Br J Pharmacol"},{"issue":"126","key":"697_CR2","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"2012","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, American College of Cardiology Foundation\/American Heart Association Task Force, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;2012(126):e354\u2013471.","journal-title":"Circulation"},{"issue":"127","key":"697_CR3","first-page":"e663","volume":"2013","author":"JL Anderson","year":"2012","unstructured":"Anderson JL, Adams CD, Antman EM, American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, et al. 2012 ACCF\/AHA focused update incorporated into the ACCF\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;2013(127):e663\u2013828.","journal-title":"Circulation"},{"key":"697_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1527-3466.1999.tb00008.x","volume":"17","author":"A Subissi","year":"1999","unstructured":"Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev. 1999;17:115\u201333.","journal-title":"Cardiovasc Drug Rev"},{"key":"697_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1023\/A:1015823315983","volume":"9","author":"SA Ranadive","year":"1992","unstructured":"Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural\u2013pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res. 1992;9:1480\u20136.","journal-title":"Pharm Res"},{"issue":"7","key":"697_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.5603\/KP.2013.0152","volume":"71","author":"F Corso Del","year":"2013","unstructured":"Del Corso F, Pareo I, Borghi C. Evolving concept of cardioprotection in myocardial infarction: from SMILE-1 to SMILE-5. Kardiol Pol. 2013;71(7):667\u201374.","journal-title":"Kardiol Pol"},{"issue":"1","key":"697_CR7","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ahj.2004.03.025","volume":"148","author":"C Napoli","year":"2004","unstructured":"Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148(1):e5.","journal-title":"Am Heart J"},{"key":"697_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/cvr\/cvu026","volume":"102","author":"M Bucci","year":"2014","unstructured":"Bucci M, Vellecco V, Cantalupo A, et al. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc Res. 2014;102:138\u201347.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"697_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0306-3623(99)00043-9","volume":"33","author":"C Napoli","year":"1999","unstructured":"Napoli C, Cicala C, D\u2019Armiento FP, et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen Pharmacol. 1999;33(6):467\u201377.","journal-title":"Gen Pharmacol"},{"issue":"1\u20132","key":"697_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11010-011-0766-9","volume":"352","author":"V Carnicelli","year":"2011","unstructured":"Carnicelli V, Frascarelli S, Zucchi R. Effect of acute and chronic zofenopril administration on cardiac gene expression. Mol Cell Biochem. 2011;352(1\u20132):301\u20137.","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"697_CR11","doi-asserted-by":"publisher","first-page":"e003531","DOI":"10.1161\/JAHA.116.003531","volume":"5","author":"E Donnarumma","year":"2016","unstructured":"Donnarumma E, Ali MJ, Rushing AM, et al. Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability. J Am Heart Assoc. 2016;5(7):e003531.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"697_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJM199501123320203","volume":"332","author":"E Ambrosioni","year":"1995","unstructured":"Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332(2):80\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"697_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1067\/mhj.2003.24","volume":"145","author":"C Borghi","year":"2003","unstructured":"Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145(1):80\u20137.","journal-title":"Am Heart J"},{"key":"697_CR14","doi-asserted-by":"publisher","first-page":"445.e7","DOI":"10.1016\/j.ahj.2006.12.005","volume":"153","author":"C Borghi","year":"2007","unstructured":"Borghi C, Ambrosioni E, Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J. 2007;153:445.e7\u201314.","journal-title":"Am Heart J"},{"issue":"7","key":"697_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/clc.22017","volume":"35","author":"C Borghi","year":"2012","unstructured":"Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G, SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol. 2012;35(7):416\u201323.","journal-title":"Clin Cardiol"},{"issue":"1","key":"697_CR16","doi-asserted-by":"publisher","first-page":"e000220","DOI":"10.1136\/openhrt-2014-000220","volume":"2","author":"C Borghi","year":"2015","unstructured":"Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart. 2015;2(1):e000220.","journal-title":"Open Heart."},{"issue":"4","key":"697_CR17","doi-asserted-by":"publisher","first-page":"147032031665648","DOI":"10.1177\/1470320316656480","volume":"17","author":"C Borghi","year":"2016","unstructured":"Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E, SMILE-4 Working Party. Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study. J Renin Angiotensin Aldosterone Syst 2016;17(4):1470320316656480.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"697_CR18","doi-asserted-by":"crossref","unstructured":"Borghi C, Ambrosioni E, Omboni S, et al. D. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. Clinicoecon Outcomes Res. 2013;5:317-325.","DOI":"10.1016\/j.jval.2013.03.1487"},{"key":"697_CR19","unstructured":"Diagnosis-Related Groups in Europe. Towards efficiency and quality. http:\/\/www.eurodrg.eu\/ . Accessed 13 Feb 2014."},{"key":"697_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/heart.85.5.539","volume":"85","author":"IS Malik","year":"2001","unstructured":"Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart. 2001;85:539\u201343.","journal-title":"Heart"},{"key":"697_CR21","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0735-1097(02)01737-0","volume":"39","author":"AM Richards","year":"2002","unstructured":"Richards AM, Nicholls MG, Troughton RW, et al. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"697_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/HJH.0b013e3283605cd8","volume":"31","author":"C Borghi","year":"2013","unstructured":"Borghi C, Ambrosioni E, Omboni S, SMILE-4 Working Party, et al. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens. 2013;31:1256\u201364.","journal-title":"J Hypertens"},{"key":"697_CR23","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","volume":"25","author":"M Bartnik","year":"2004","unstructured":"Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J. 2004;25:1880\u201390.","journal-title":"Eur Heart J"},{"key":"697_CR24","doi-asserted-by":"publisher","first-page":"145615","DOI":"10.4061\/2011\/145615","volume":"2011","author":"B Ovbiagele","year":"2011","unstructured":"Ovbiagele B, Markovic D, Fonarow CG. Recent US patterns and predictors of prevalent diabetes among acute myocardial infarction patients. Cardiol Res Pract. 2011;2011:145615.","journal-title":"Cardiol Res Pract"},{"key":"697_CR25","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2337\/diacare.26.6.1862","volume":"26","author":"C Borghi","year":"2003","unstructured":"Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E, on behalf of the SMILE Study Investigators. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care. 2003;26:1862\u20138.","journal-title":"Diabetes Care"},{"key":"697_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/1755-5922.12175","volume":"34","author":"C Borghi","year":"2016","unstructured":"Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E, SMILE-4 Working Party. Zofenopril and ramipril in combination with Acetyl Salicylic Acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis of the SMILE-4 randomized, double-blind study in diabetic patients. Cardiovasc Ther. 2016;34:76\u201384.","journal-title":"Cardiovasc Ther"},{"key":"697_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2009.03.007","volume":"2","author":"DE Hofsten","year":"2009","unstructured":"Hofsten DE, Logstrup BB, Moller JE, Pellika PA, Egstrup K. Abnormal glucose metabolism in acute myocardial infarction. JACC Cardiovasc Imaging. 2009;2:592\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"key":"697_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1475-2840-11-78","volume":"11","author":"M Mazurek","year":"2012","unstructured":"Mazurek M, Kowalczyk J, Lenarczyk R, et al. The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol. 2012;11:78.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"697_CR29","doi-asserted-by":"publisher","first-page":"e000195","DOI":"10.1136\/openhrt-2014-000195","volume":"2","author":"C Borghi","year":"2015","unstructured":"Borghi C, Omboni S, Cicero AF, et al. Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. Open Heart. 2015;2(1):e000195.","journal-title":"Open Heart"},{"key":"697_CR30","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB, Chamber Quantification Writing Group, American Society of Echocardiography\u2019s Guidelines and Standards Committee, European Association of Echocardiography, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440\u201363.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"697_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/FJC.0000000000000473","volume":"69","author":"C Borghi","year":"2017","unstructured":"Borghi C, Omboni S, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Early treatment with zofenopril and ramipril in combination with acetyl salicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a 5-year follow-up of patients of the Smile-4 Study. J Cardiovasc Pharmacol. 2017;69(5):298\u2013304.","journal-title":"J Cardiovasc Pharmacol"},{"key":"697_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1503\/cmaj.060068","volume":"178","author":"L Pilote","year":"2008","unstructured":"Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. Can Med Assoc J. 2008;178:1303\u201311.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"697_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.amjcard.2013.02.058","volume":"112","author":"C Borghi","year":"2013","unstructured":"Borghi C, Cosentino ER, Rinaldi ER, Cicero AF. Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am J Cardiol. 2013;112(1):90\u20133.","journal-title":"Am J Cardiol"},{"key":"697_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/1077558712448467","volume":"69","author":"RM Coffey","year":"2012","unstructured":"Coffey RM, Misra A, Barrett M, Andrews RM, Mutter R, Moy E. Congestive heart failure: who is likely to be readmitted? Med Care Res Rev. 2012;69:602\u201316.","journal-title":"Med Care Res Rev"},{"key":"697_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pcad.2011.04.002","volume":"54","author":"C Norton","year":"2011","unstructured":"Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:78\u201385.","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0697-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0697-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0697-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T01:54:38Z","timestamp":1571190878000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0697-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["697"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0697-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"14 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}